Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Harris, Ginny Marie ^a   Dodelzon, Katerina ^a   Gong, Lijie ^b   Gonzalez Alegre, Pedro ^a   Paulson, Henry L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; MESSENGER RNA; POLYGLUTAMINE; PROTEASOME; ATXN3 PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN MOTIF; TRINUCLEOTIDE REPEAT; UBIQUITINATION; ANIMAL; BRAIN; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; BRAIN; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS;

EID: 78149430698     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013695     Document Type: Article

References (42)

1. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.
2. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302(5653): 2141-2144.
3. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456(7221): 470-476.
4. Tsunemi T, Ishikawa K, Jin H, Mizusawa H (2008) Cell-type-specific alternative splicing in spinocerebellar ataxia type 6. Neuroscience Letters 447(1): 78-81.
5. Tadokoro K, Yamazaki-Inoue M, Tachibana M, Fujishiro M, Nagao K, et al. (2005) Frequent occurrence of protein isoforms with or without a single amino acid residue by subtle alternative splicing: the case of Gln in DRPLA affects subcellular localization of the products. J Hum Genet 50(8): 382-394.
6. Sahba S, Nechiporuk A, Figueroa KP, Nechiporuk T, Pulst SM (1998) Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. Genomics 47(3): 359-364.
7. Reid SJ, Whittaker DJ, Greenwood D, Snell RG (2009) A splice variant of the TATA-box binding protein encoding the polyglutamine-containing N-terminal domain that accumulates in Alzheimer's disease. Brain Res 1268: 190-199.
8. Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, et al. (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41(4): 453-462.
9. Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, et al. (2001) The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet 46(7): 413-422.
10. Hirata S, Shoda T, Kato J, Hoshi K (2003) Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends Endocrinol Metab 14(3): 124- 129.
11. Goto J, Watanabe M, Ichikawa Y, Yee SB, Ihara N, et al. (1997) Machado-Joseph disease gene products carrying different carboxyl termini. Neurosci Res 28(4): 373-377.
12. Einum DD, Clark AM, Townsend JJ, Ptacek LJ, Fu YH (2003) A novel central nervous system-enriched spinocerebellar ataxia type 7 gene product. Arch Neurol 60(1): 97-103.
13. Bettencourt C, Santos C, Montiel R, Costa MD, Cruz-Morales P, et al. (2010) Increased transcript diversity: novel splicing variants of Machado-Joseph Disease gene (ATXN3). Neurogenetics 11(2): 193-202.
14. Banfi S, Servadio A, Chung MY, Kwiatkowski TJ, Jr., McCall AE, et al. (1994) Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 7(4): 513-520.
15. Affaitati A, de Cristofaro T, Feliciello A, Varrone S (2001) Identification of alternative splicing of spinocerebellar ataxia type 2 gene. Gene 267(1): 89-93.
16. Winborn BJ, Travis SM, Todi SV, Scaglione KM, Xu P, et al. (2008) The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 283(39): 26436-2643.
17. Todi SV, Winborn BJ, Scaglione KM, Blount JR, Travis SM, et al. (2009) Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J 28(4): 372- 382.
18. Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, et al. (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 362(3): 734-739.
19. Burnett B, Li F, Pittman RN (2003) The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 12(23): 3195-205.
20. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, et al. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8(3): 221-228.
21. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, et al. (1998) An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 8(4): 669-679.
22. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, et al. (2002) YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 11(9): 1075-1094.
23. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, et al. (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 24(45): 10266-10279.
24. Todi SV, Laco MN, Winborn BJ, Travis SM, Wen HM, et al. (2007) Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J Biol Chem 282(40): 29348-29358.
25. Chai Y, Shao J, Miller VM, Williams A, Paulson HL (2002) Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 99(14): 9310-9315.
26. do Carmo Costa M, Sequeiros J, Maciel P (2002) Identification of three novel polymorphisms in the MJD1 gene and study of their frequency in the Portuguese population. J Hum Genet 47(4): 205-207.
27. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, et al. (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452(7188): 713-718.
28. Matsuyama Z, Yanagisawa NK, Aoki Y, Black Iii JL, Lennon VA, et al. (2004) Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel-loss-of-function cellular model of SCA6. Neurobiology of Disease 17(2): 198-204.
29. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, et al. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18(1): 37-48.
30. Berke SJ, Chai Y, Marrs GL, Wen H, Paulson HL (2005) Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem 280(36): 32026-32034.
31. Bichelmeier U, Schmidt T, Hubener J, Boy J, Ruttiger L, et al. (2007) Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 27(28): 7418-7428.
32. Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL (2009) In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis 33(3): 342-353.
33. Fisher RD, Wang B, Alam SL, Higginson DS, Robinson H, et al. (2003) Structure and ubiquitin binding of the ubiquitin-interacting motif. J Biol Chem 278(31): 28976-28984.
34. Yang F, Yang YP, Mao CJ, Cao BY, Cai ZL, et al. (2009) Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein. Neurosci Lett 454(3): 203-208.
35. Saunders HM, Bottomley SP (2009) Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Protein Eng Des Sel 22(8): 447-451.
36. Ellisdon AM, Thomas B, Bottomley SP (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281(25): 16888-16896.
37. Silva AL, Romao L (2009) The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision? FEBS Lett 583(3): 499-505.
38. Maquat LE (2005) Nonsense-mediated mRNA decay in mammals. J Cell Sci 118(9): 1773-1776.
39. Mueller T, Breuer P, Schmitt I, Evert BO, Wullner U (2009) CK2-Dependent Phosphorylation Determines Cellular Localization and Stability of Ataxin-3. Hum Mol Genet 12(17): 3334-3343.
40. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, et al. (1998) Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 143(6): 1457-1470.
41. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, et al. (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polygluta-mine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 15(1): 62-69.
42. Kanumilli S, Tringham EW, Elizabeth Payne C, Dupere JRB, Venkateswarlu K, et al. (2006) Alternative splicing generates a smaller assortment of CaV2.1 transcripts in cerebellar Purkinje cells than in the cerebellum. Physiol Genomics 24(2): 86-96.